Slide Resources

 

Here, you can search through all the slide resources available on this website: slide-sets from Meeting ResourcesESMO E-Learning modules; and Educational Slides.

 




Format available

https://oncologypro.esmo.org/Meeting-Resour...s-Implications-for-design-of-clinical-trials

It has been shown that mutations alone are not the sole determinant of response to targeted agents, for example, BRAF mutations predict response to BRAF inhibitors in melanoma but not colon cancer due...

Date: 06 Mar 2018
Section: Meeting Resources

https://oncologypro.esmo.org/Meeting-Resour...atients-with-Relapsed-or-Refractory-Lymphoma

NF-kB has been found to be constitutively activated in many lymphomas, such as diffuse large B-cell lymphomas (DLBCL), particularly the ABC subgroup. In preclinical studies, CPI-0610, a BET specific...

Date: 06 Mar 2018
Section: Meeting Resources
Topics: Anti-Cancer Agents & Biologic Therapy, Lymphomas, Haematologic Malignancies

https://oncologypro.esmo.org/Meeting-Resour...ary-Safety-in-Patients-with-B-Cell-Lymphomas

EZH2 is the catalytic subunit of the PRC2 complex, and plays an important role in transcriptional repression. EZH2 over-expression is correlated with poor prognosis.

Date: 06 Mar 2018
Section: Meeting Resources
Topics: Anti-Cancer Agents & Biologic Therapy, Lymphomas, Haematologic Malignancies

https://oncologypro.esmo.org/Meeting-Resour...-5461-in-Patients-with-Advanced-Solid-Tumors

G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions that can lead to replication fork collapse and double-stranded DNA breaks.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Anti-Cancer Agents & Biologic Therapy

https://oncologypro.esmo.org/Meeting-Resour...-cell-metabolism-and-metabolic-reprogramming

Date: 06 Mar 2018
Section: Meeting Resources

https://oncologypro.esmo.org/Meeting-Resour...ginine-Deprivation-in-ASS1-Deficient-Cancers

Argininosuccinate Synthetase 1 (ASS1) is silenced in ∼90% of sarcomas. Loss of this urea cycle enzyme causes cells to become dependent upon extracellular arginine for continued cell growth and proliferation.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Palliative and Supportive Care

https://oncologypro.esmo.org/Meeting-Resour...ays-to-harness-targeting-DNA-to-treat-cancer

Date: 06 Mar 2018
Section: Meeting Resources
Topics: Biomarkers, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...cer-Therapies/Novel-topoisomerase-inhibitors

DNA topoisomerases are validated targets for a broad range of widely used anticancer drugs. They include the topoisomerase II (TOP2) inhibitors, etoposide, teniposide, doxorubicin, daunorubicin and...

Date: 06 Mar 2018
Section: Meeting Resources

https://oncologypro.esmo.org/Meeting-Resour...-and-immunotherapy-Synergies-of-combinations

In cancer the presence of T cell immune infiltration has been recognised as a prognostic factor, however the mechanisms underpinning this response are not clearly defined.

Date: 06 Mar 2018
Section: Meeting Resources
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...of-CDK4-6-inhibition-Induction-of-senescence

CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated (WDLS) and dedifferentiated (DDLS) liposarcoma we had previously suggested that their clinical promise...

Date: 07 Mar 2018
Section: Meeting Resources